September 17, 2025DrugsOpen Access

The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This review assesses remyelination in multiple sclerosis, emphasizing trial design and therapeutic implications.

Remyelination has shown feasibility in multiple sclerosis patients, indicating promising therapeutic potential.
Phase II trials provide evidence for remyelination, yet many drug development programs faced challenges in effectiveness.
Refined methodologies are needed for clinical trials, including better patient selection and validation of biomarkers.
Improving trial design could advance multiple sclerosis therapeutics by addressing key questions in remyelination.

Zuroff et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark